Sabby Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Sabby Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,277	Closed	-$276K	–	411
2015 Q4	$276K	Sell	2,277 -500	-18%	-$1.6K	0.02%	272
2015 Q3	$2.06M	Buy	2,777 +500	+22%	+$3.82K	0.09%	152
2015 Q2	$1.63M	Buy	2,277 +524	+30%	+$4.08K	0.06%	187
2015 Q1	$1.51M	Buy	1,753 +5	+0.3%	+$45	0.06%	163
2014 Q4	$1.74K	Buy	1,748 +661	+61%	+$5.64K	0.06%	136
2014 Q3	$1.08K	Buy	+1,087	New	+$16.1K	0.04%	153
2014 Q1	–	Sell	-265	Closed	-$485K	–	324
2013 Q4	$485K	Sell	265 -600	-69%	-$11.3K	0.03%	153
2013 Q3	$2.32M	Buy	865 +665	+333%	+$14.3K	0.15%	74
2013 Q2	$369K	Buy	+200	New	+$3.53K	0.02%	150

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sabby Management's RPRX Position: Q3 2015 in Review

Sabby Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 41,643 shares — an estimated $318K sold.

Sabby Management first reported a position in RPRX in Q2 2013 and held it in 6 quarters. The position peaked at $3.96M in Q3 2013. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

Sabby Management reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
Sabby Management sold 41,643 Repros Therapeutics Inc. shares in Q3 2015, an estimated $318K.
Sabby Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 6 quarters.
Sabby Management's Repros Therapeutics Inc. position peaked at $3.96M in Q3 2013.
58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.